Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Jennifer Clarke

University of California, San Francisco

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Collaborators (3)

Javier Villanueva-Meyer

Associate Professor

University of California, San Francisco

UNITED STATES

Ingo Mellinghoff

Department Chair

Memorial Sloan Kettering Cancer Center

UNITED STATES

Takahide Nejo

University of California, San Francisco

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jennifer Clarke

Research Interests

Make your next move.

Explore related searches

Articles (20)

Collaborators (3)

Javier Villanueva-Meyer

Ingo Mellinghoff

Takahide Nejo

Make your next move.

Jennifer Clarke

Research Interests

Make your next move.

Explore related searches

Articles (20)

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY)

Exploratory Analyses from the Phase Three INDIGO Study Suggest Potential Mechanism of Seizure Control Through Tumor Volume Reduction Under Treatment With Vorasidenib (S28.002)

A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): Updated efficacy and safety.

An intervention in disguise: An immersive care model for families where a parent has a brain tumor.

Impact of vorasidenib vs placebo on seizure rates and quality of life: Exploratory analysis from the phase 3 INDIGO study.

AAV immuno-gene therapy platform delivering vectorized cytokines defines a new modality for high-grade glioma treatment

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma

Abstract CT042: First-in-human trial of E-SYNC T-cells, an autologous anti-EGFRvIII SynNotch receptor-induced anti-EphA2/IL13Ra2 CAR T-cells, in adult patients with EGFRvIII+ glioblastoma

Abstract A043: Genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastoma

Abstract A061: Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses

CTIM-08. OPERATIONAL STRATEGIES AND REGULATORY NAVIGATION OF AN ACADEMIC CAR T-CELL TRIAL FOR GLIOBLASTOMA: EXPERIENCE FROM THE E-SYNC STUDY

10204-CS-21 Exploratory analyses from the INDIGO study on the mechanism of seizure control by vorasidenib through tumor volume reduction

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial

BIOM-99. IDENTIFY OLIGODENDROGLIOMA PATIENT SURVIVAL GROUPS BY RECURSIVE PARTITION ANALYSIS

IMG-89. Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

INNV-06. Build it and they will come: Cognitive rehabilitation in primary brain tumor

QOL-02. Tele-Cognitive rehabilitation for adult lower grade glioma: A prospective feasibility study

TIP-08. Trial in progress update: A phase 1/2 study of intracranial and intravenous multi-dosing of DB107-RRV (formerly Toca 511) and DB107-FC (5-fluorocytosine) in combination with radiation ± temozolomide (TMZ) in patients with newly diagnosed high-grade gliomas (HGGs)

JS05.6.A EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB

Collaborators (3)

Javier Villanueva-Meyer

Ingo Mellinghoff

Takahide Nejo

Make your next move.